|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E mutation is a distinctive genomic alteration of pediatric low-grade gliomas with prognostic and therapeutic implications.
|
31667545 |
2020 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Whereas both H3F3A K27M and BRAF V600E have been reported as poor prognostic markers in pediatric glioma, our case, along with several other reported cases, suggests that the coexistence of these two mutations might not indicate poor prognosis.
|
31254135 |
2019 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF-V600E mutations are most commonly found in pleomorphic xanthoastrocytoma, ganglioglioma, epithelioid glioblastoma, and gliomas diagnosed at a younger age; BRAF-KIAA1549 fusion is the most common BRAF alteration in pilocytic astrocytoma.
|
30265855 |
2018 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Additionally, BRAF V600E was only associated with a favorable prognosis in lower grade glioma.
|
28534272 |
2018 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Taken together with the facts that only one PXA preceded E-GBM among these lower-grade lesions, and that co-occurrence of BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions have been reported to be rare in conventional lower-grade diffuse gliomas, the diffuse glioma-like components may be distinct infiltrative components of E-GBM, reflecting intratumoral heterogeneity.
|
29105198 |
2018 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas.
|
28727518 |
2017 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A phase I/II clinical trial suggests that dabrafenib shrinks or stabilizes low-grade gliomas in children with the BRAF V600E mutation.
|
28062673 |
2017 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These findings are consistent with clonal expansion of a morphologically distinct focus, harboring a private BRAF V600E mutation within an IDH1-mutant glioma.
|
26414224 |
2016 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma.
|
26384810 |
2016 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
For colorectal carcinoma, thyroid cancer, malignant melanoma and gliomas BRAF V600E immunostaining is sufficient for screening purposes.
|
27350555 |
2016 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We discuss differential diagnosis of the tumor, and review previously described diffuse gliomas with the BRAF V600E mutation.
|
26445861 |
2016 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our data indicate that BRAF(V600E) is a common genetic alteration in low-grade glial tumors with neuronal component or differentiation.
|
25346165 |
2015 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We demonstrated that overexpression of PTPN9 reduces EGFR phosphorylation and cooperates with BRAF(V</span>600E</span>) in</span>hibitor PLX4720 to reduce MAPK and Akt signaling, resulting in decreased glioma cell viability.
|
26023796 |
2015 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Although this glioma was difficult to clarify, diagnosis of pleomorphic xanthoastrocytoma with anaplastic feature was suggested based on the association of some pathological feature (eosinophilic granular bodies, reticulin network and diffuse CD34 expression) and the BRAF V600E mutation.
|
24857351 |
2014 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
However, a previous study on BRAF V600E mutation in paediatric glioma revealed a BRAF mutation in one of two tested DIAs/DIGs.
|
23822828 |
2014 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF blockade with UAI-201 resulted in dose-dependent inhibition of MEK/ERK phosphorylations and increased G0/G1 arrest in glioma cells with BRAF-V600E.
|
24721513 |
2014 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The data further support previous observations that these two alterations of the BRAF, KIAA1549 fusions and V600E point mutations, are associated primarily with pilocytic astrocytomas and nonpilocytic gliomas, respectively.
|
21884820 |
2011 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Using the BRAF(V600E)-specific inhibitor PLX4720, pharmacologic blockade of BRAF revealed preferential antiproliferative activity against BRAF(V600E) mutant cells in vitro, in contrast to the use of shRNA-mediated knockdown of BRAF, which inhibited cell growth of glioma cell lines regardless of BRAF mutation status.
|
22038996 |
2011 |